• [Shinhan Investment] Eoflow: Potential to Grow Bigger Than Insulet

    Mar.11.2021
  • Jan 20, 2021 [EOFlow] Potential to grow bigger than Insulet.PDF (1,085,162k)
  • EOFlow is sharing full English version of an analyst report from Shinhan Investment Corp. published on January 20th. 
    The report is written by two pharmaceutical/bio analysts DongGun Lee and JaeHee Won.

    They commented that Eoflow is expected to launch EOPatch in the domestic market in 1Q21. They stated that the company plans to sell the flagship product through its domestic partner Huons, and apply for national health insurance coverage to accelerate market penetration.
    They stated that the CE marking to sell in Europe will likely be obtained within 1H21. Significant sales from Europe can be expected in 2H21 through partnership with A. Menarini Diagnostics.
    Insulet currently has a market cap of about KRW21tr.
    Analysts found that Eoflow more attractive than Insulet in light of: 1) EOPatch launch in Korea/Europe slated for 1H21; and 2) expansion into markets for wearable artificial pancreas/kidney and non-insulin drug delivery solutions.

    Check out the related article on Business Korea. 
    http://www.businesskorea.co.kr/news/articleView.html?idxno=58945

    Thank you for your interest and support, and we will always keep you posted!
    If you have further questions, please send an email to ir.pr@eoflow.com.

     

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here

PRIVACY POLICY